Israeli pharma touts PhIII for premature infant intestinal malady; Novartis backs a British biotech's Series B
An Israeli pharma company touted a Phase III win early Wednesday, a path it says will take it hurtling toward another pivotal study later this year.
Elgan Pharma said the Phase III for its insulin formulation to treat intestinal malabsorption, which causes feeding intolerance in premature infants, hit statistical significance in its primary endpoint. The company had been aiming to measure whether the infants could intake at least 150 ml/kg/day of food for 3 consecutive days at a significantly higher rate than placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
